Actively Recruiting
A Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEMI)
Led by ResoTher Pharma · Updated on 2025-09-22
96
Participants Needed
1
Research Sites
74 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an exploratory, randomized, double-blind, multicentre, placebo-controlled study of RTP-026. The study population will consist of men and women with documented evidence of ST-elevation myocardial infarction (STEMI) referred to primary Percutaneous Coronary Intervention (PCI).
CONDITIONS
Official Title
A Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEMI)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provided informed consent before starting any study procedures
- Men between 18 and 85 years old or post-menopausal women up to 85 years old
- Chest pain started less than 12 hours ago
- Confirmed STEMI by ECG criteria
- Eligible for primary Percutaneous Coronary Intervention (PCI)
- Neutrophil to lymphocyte ratio (NLR) between 7 and 17 at hospital admission; for chest pain lasting more than 3 to 6 hours or less than 3 hours, NLR between 4.8 and 17 or neutrophil count at least 9 x 10^9/L regardless of lymphocyte count
- For anterior or anterolateral infarction STEMI patients, NLR at least 3
You will not qualify if you...
- Participated in another investigational drug study within the past 4 weeks
- Previous exposure to RTP-026
- Time from symptom onset to primary PCI more than 12 hours
- Previous coronary artery bypass graft surgery (CABG)
- Active malignant disease
- Currently on immune suppressive treatment
- Any condition that may prevent compliance with the study protocol
- Known contraindications to cardiac magnetic resonance imaging (CMR)
- ORBI Risk Score greater than 12
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hjertecenteret, Rigshospitalet
Copenhagen, Denmark, 2100
Actively Recruiting
Research Team
I
Irene Sandholdt
CONTACT
S
Samra J Sanni, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here